Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma
M Swamydas, EV Murphy, JJ Ignatz-Hoover… - Journal of Hematology & …, 2022 - Springer
Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …
Multiple myeloma therapy: emerging trends and challenges
Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …
Leukocyte immunoglobulin-like receptor B1 (LILRB1) protects human multiple myeloma cells from ferroptosis by maintaining cholesterol homeostasis
Multiple myeloma (MM) is a hematologic malignancy characterized by uncontrolled
proliferation of plasma cells in the bone marrow. MM patients with aggressive progression …
proliferation of plasma cells in the bone marrow. MM patients with aggressive progression …
Perspectives of targeting LILRB1 in innate and adaptive immune checkpoint therapy of cancer
T Zeller, IA Münnich, R Windisch, P Hilger… - Frontiers in …, 2023 - frontiersin.org
Immune checkpoint blockade is a compelling approach in tumor immunotherapy. Blocking
inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer …
inhibitory pathways in T cells has demonstrated clinical efficacy in different types of cancer …
Targeting NK cell inhibitory receptors for precision multiple myeloma immunotherapy
Innate immune surveillance of cancer involves multiple types of immune cells including the
innate lymphoid cells (ILCs). Natural killer (NK) cells are considered the most active ILC …
innate lymphoid cells (ILCs). Natural killer (NK) cells are considered the most active ILC …
Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer
Inhibitory leukocyte immunoglobulin-like receptors (LILRBs 1–5) transduce signals via
intracellular immunoreceptor tyrosine-based inhibitory motifs that recruit phosphatases to …
intracellular immunoreceptor tyrosine-based inhibitory motifs that recruit phosphatases to …
Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma
Purpose: T-cell immunoreceptor with Ig and ITIM domain (TIGIT) blockade could represent
an alternative therapeutic option to release the immune response in patients with multiple …
an alternative therapeutic option to release the immune response in patients with multiple …
Deregulation of adaptive T cell immunity in multiple myeloma: insights into mechanisms and therapeutic opportunities
N Leblay, R Maity, F Hasan, P Neri - Frontiers in oncology, 2020 - frontiersin.org
Immunotherapy has recently emerged as a promising treatment option for multiple myeloma
(MM) patients. Profound immune dysfunction and evasion of immune surveillance are …
(MM) patients. Profound immune dysfunction and evasion of immune surveillance are …
[HTML][HTML] Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells
Background Current immune checkpoint blockade strategies have been successful in
treating certain types of solid cancer. However, checkpoint blockade monotherapies have …
treating certain types of solid cancer. However, checkpoint blockade monotherapies have …
[HTML][HTML] Enhanced expression of FCER1G predicts positive prognosis in multiple myeloma
L Fu, Z Cheng, F Dong, L Quan, L Cui, Y Liu… - Journal of …, 2020 - ncbi.nlm.nih.gov
Background: Multiple myeloma (MM) is the second most common hematologic malignancy
worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE …
worldwide and does not have sufficient prognostic indicators. FCER1G (Fc fragment Of IgE …